貝瑞基因(000710.SZ):杭州貝瑞NextSeq CN500基因測序儀獲得延續註冊
格隆匯11月19日丨貝瑞基因(000710.SZ)公佈,公司全資子公司杭州貝瑞和康基因診斷技術有限公司(“杭州貝瑞”)於近日收到國家藥品監督管理局頒發的《中華人民共和國醫療器械註冊證》,杭州貝瑞NextSeq CN500基因測序儀獲得延續註冊。
NextSeq CN500基因測序儀獲得延續註冊是繼NextSeq CN500基因測序儀完成適用範圍變更,成為可以應用於包括腫瘤學基因檢測的通用型臨牀NGS測序平台後,公司在基因檢測領域持續競爭力的延續。本次醫療器械註冊證的獲得使公司可以繼續生產及銷售上述產品,保證了公司基因檢測相關產品線收入的持續性,對公司未來經營將產生積極影響。上述產品的實際生產及銷售情況取決於未來市場推廣效果,公司目前尚無法預測其對公司未來業績的影響,敬請廣大投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.